Maternal vaccines are immunizations administered to pregnant individuals to provide protection against certain infections for both the mother and the newborn. These vaccines aim to confer passive immunity to the infant during the vulnerable period when they are too young to receive vaccinations themselves. Common maternal vaccines include the influenza vaccine, which helps prevent flu-related complications during pregnancy, and the Tdap vaccine, which protects against tetanus, diphtheria, and pertussis. Additionally, maternal immunization against certain infections, such as Group B Streptococcus and Hepatitis B, is recommended in specific situations. Maternal vaccination is a critical component of prenatal care, reducing the risk of adverse outcomes for both the mother and the infant. The antibodies generated in response to vaccination are transferred across the placenta, offering protection to the newborn during the first months of life. Promoting awareness, education, and access to maternal vaccines is essential for optimizing maternal and child health outcomes. Ongoing research aims to expand the range of vaccines available for maternal immunization and enhance global efforts to protect vulnerable populations during pregnancy.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States